OSE Immuno: receives 1.5 ME funding from Bpifrance
This funding is aimed at accelerating the development of an innovative companion diagnostic test based on a simple blood sample.
It should enable the identification of HLA-A2 positive non-small cell lung cancer (NSCLC) patients eligible for treatment with Tedopi® (OSE Immuno's NSCLC vaccine) in the upcoming pivotal Phase 3 clinical trial.
The aim of this final stage of clinical development is to confirm the efficacy and safety of Tedopi® in second-line treatment after failure of checkpoint inhibitors (CPIs) in HLA-A2 positive NSCLC patients.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction